DANVILOSTOMIG
UNII B4Q67YX49Q

Substance Identification & Data

This profile provides standardized clinical and technical data for Danvilostomig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) B4Q67YX49Q.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2599198-80-6 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

B4Q67YX49Q

CAS Registry Number

2599198-80-6

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

DANVILOSTOMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C178449

National Cancer Institute reference terminology for clinical and research data.

INN ID

12198

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Danvilostomig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Danvilostomig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Danvilostomig

Common Names & Synonyms

Immunoglobulin G1 [235-alanine,236-alanine,238-alanine,322-alanine,de-448-lysine], bispecific, anti-(human cytotoxic T-lymphocyte-associated protein 4) (human monoclonal MDX010 γ1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human programmed cell death protein 1) (human-Oryctolagus cuniculus clone PD224D1 single-chain variable fragment VH-(GGGGS)4-VL), disulfide with human monoclonal MDX010 κ-chain, dimer

danvilostomig [INN]

immunoglobulin G1-kappa_scFv, anti-[Homo sapiens CTLA4 (cytotoxic T-lymphocyte-associated antigen 4, cytotoxic T-lymphocyte-associated protein 4, CTLA-4, CD152)], each heavy chain being fused to a scFv anti-[Homo sapiens PDCD1 (programmed cell death 1, PD1, PD-1, CD279)], Homo sapiens and humanized monoclonal antibody, tetravalent, bispecific, gamma1 heavy chain anti-CTLA4 Homo sapiens fused to scFv anti-PDCD1 humanized (1-701)[gamma1 heavy chain anti-CTLA4 Homo sapiens (1-447)[VH (Homo sapiens IGHV3-30*01 (94.9%)-(IGHD)-IGHJ4*01 (100%), CDR-IMGT [8.8.11] (26-33.51-58.97-107))(1-118)-Homo sapiens IGHG1*01v, G1m17,1>G1m3,1, G1v14-1 CH2 A1.3, A1.2, A1, G1v20 CH2 A105 (CH1 K120>R(215)(119-216), hinge 1-15 (217-231), CH2 L1.3>A (235), L1.2>A(236), G1>A (238), K105>A (323)(232-341), CH3 D12 (357), L14(359)(342-446), CHS (447))(119-447)] -10-mer bis(tetraglycyl-seryl)linker (448-457)-scFv-VH-V-KAPPA anti-PDCD1 (458-701)[VH (Homo sapiens GHV3-64*04 (76.5%)-(IGHD)-IGHJ4*01(86.7%), CDR-IMGT [8.7.9] (483-490.508-514.553-561))(458-572)-20-mer tetrakis(tetraglycyl-seryl)linker (573-592)-V-KAPPA(Homo sapiens IGKV1-27*01 (88.0%)-IGKJ4*01 (100%), CDR-IMGT [6.3.11] (619-624.642-644.681-691))(593-701)], (221-215')-disulfide with kappa light chain anti-CTLA4 Homo sapiens (1'-215')[V-KAPPA (Homo sapiens IGKV3-20*01(97.9%)-IGKJ1*01(100%), CDR-IMGT [7.3.9] (27-33.51-53.90-98))(1'-108')-Homo sapiens IGKC*01 (100%), Km3 A45.1 (154), V101 (192)(109'-215')], dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO)cells, glycoform alfa

External Clinical & Regulatory Resources

Previous UNIIB4PT6I4HNT

Next UNIIB4Q97FDN44